Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: The ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: Study protocol for a cluster randomised controlled trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Iwuji, Collins C ^a   Orne Gliemann, Joanna ^b,c   Tanser, Frank ^a   Boyer, Sylvie ^d,e,f   Lessells, Richard J ^a,g   Lert, France ^h,i   Imrie, John ^a,j   Bärnighausen, Till ^a,k   Rekacewicz, Claire ^l   Bazin, Brigitte ^l   Newell, Marie Louise ^a,m   Dabis, François ^b,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d AIX MARSEILLE UNIV   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l Unit for Basic and Clinical Research on Viral Hepatitis   (France)

^m UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

more..

Author keywords

Antiretroviral therapy; HIV infections; Prevention; South Africa

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; HEALTH IMPACT ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; SOUTH AFRICA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG RESISTANCE, VIRAL; FEASIBILITY STUDIES; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INCIDENCE; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RESEARCH DESIGN; RURAL HEALTH SERVICES; SEXUAL BEHAVIOR; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84880335035     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-230     Document Type: Article

References (47)

1. UNAIDS Report on the Global AIDS Epidemic 2012, Geneva: UNAIDS, [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf]. Accessed 18 January 2013, UNAIDS.
2. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929. 10.1056/NEJM200003303421303, 10738050.
3. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, Kornegay J, Jackson B, Moye J, Hanson C, Zorrilla C, Lew JF. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402. 10.1056/NEJM199908053410602, 10432324.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, De Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011, 365:493-505. 10.1056/NEJMoa1105243, 3200068, 21767103.
5. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013, 339:966-971. 10.1126/science.1228160, 23430656.
6. The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group HIV treatment as prevention: models, data, and questions-towards evidence-based decision-making. PLoS Med 2012, 9:e1001259. 10.1371/journal.pmed.1001259, 3393655, 22802739, The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group.
7. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57. 10.1016/S0140-6736(08)61697-9, 19038438.
8. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010, 24:729-735. 10.1097/QAD.0b013e32833433fe, 2852517, 20154580.
9. Eaton JW, Johnson LF, Salomon JA, Barnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012, 9:e1001245. 10.1371/journal.pmed.1001245, 3393664, 22802730.
10. Hontelez JAC, Lurie MN, Bärnighausen T, Bakker R, Baltussen R, Tanser F, Hallett TB, Newell M-L, De Vlas SJ. Treatment as prevention for HIV in South Africa: different models show consistency in occurrence, but difference in timing of elimination and the overall impact of the intervention. J Int AIDS Soc 2012, 15(Suppl 3).
11. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826. 10.1056/NEJMoa0807252, 2854555, 19339714.
12. Sterne JA, May M, Costagliola D, De Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363. 2670965, 19361855.
13. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Menan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012, 54:714-723. 10.1093/cid/cir898, 3275759, 22173233.
14. The ANRS 12249 study group ANRS 12249 TasP Protocol ANRS, Paris, Version 1.2. 08/03/2012, [http://mereva.isped.u-bordeaux2.fr/tasp/html/tasp_documents/fichiers/ANRS12249_TasP-Protocol-V1.2-8mars2012-Signed.pdf]. Accessed 16 July 2013, The ANRS 12249 study group.
15. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 2007, 21:1467-1472. 10.1097/QAD.0b013e3280ef6af2, 17589193.
16. Tanser F, Barnighausen T, Cooke GS, Newell ML. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol 2009, 38:1008-1016. 10.1093/ije/dyp148, 2720393, 19261659.
17. Zaidi J, Grapsa E, Tanser F, Newell M, Bärnighausen T. HIV prevalence trends after scale-up of antiretroviral treatment: a population-based study in a poor rural community in KwaZulu-Natal. J Int AIDS Soc 2012, 15(Suppl 3).
18. Barnighausen T, Tanser F, Newell ML. Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses 2009, 25:405-409. 10.1089/aid.2008.0211, 2853840, 19320571.
19. Barnighausen T, Wallrauch C, Welte A, McWalter TA, Mbizana N, Viljoen J, Graham N, Tanser F, Puren A, Newell ML. HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One 2008, 3:e3640. 10.1371/journal.pone.0003640, 2572841, 18982059.
20. Tanser F, Bärnighausen T, Newell M. Identification of Localized Clusters of High HIV Incidence in a Widely Disseminated Rural South African Epidemic: A Case for Targeted Intervention Strategies. 2011, Boston, MA (USA): 18th Conference on Retroviruses and Opportunistic Infections (CROI), Abstract 137.
21. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, Newell ML. Cohort Profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol 2011, 40:318-326. 10.1093/ije/dyp402, 3195268, 20154009.
22. Maheswaran H, Thulare H, Stanistreet D, Tanser F, Newell ML. Starting a home and mobile HIV testing service in a rural area of South Africa. J Acquir Immune Defic Syndr 2012, 59:e43-e46. 10.1097/QAI.0b013e3182414ed7, 22107821.
23. Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W, Newell C, Viljoen J, Mutevedzi T, Newell ML. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 2008, 37:956-962. 10.1093/ije/dym211, 2557060, 17998242.
24. Tanser F, Hosegood V, Benzler J, Solarsh G. New approaches to spatially analyse primary health care usage patterns in rural South Africa. Trop Med Int Health 2001, 6:826-838. 10.1046/j.1365-3156.2001.00794.x, 11679131.
25. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006, 355:1141-1153. 10.1056/NEJMsa060247, 16971720.
26. Hontelez JA, De Vlas SJ, Tanser F, Bakker R, Barnighausen T, Newell ML, Baltussen R, Lurie MN. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One 2011, 6:e21919. 10.1371/journal.pone.0021919, 3140490, 21799755.
27. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, Mayaud P, Changalucha J, Nicoll A, Ka-Gina G, Newell J, Mugeye K, Mabey D, Hayes R. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995, 346:530-536. 10.1016/S0140-6736(95)91380-7, 7658778.
28. Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet 2011, 378:247-255. 10.1016/S0140-6736(11)60779-4, 3141142, 21763937.
29. World Health Organisation Antiretroviral therapy for HIV infection in adults and adolescents Recommendations for a public health approach (2010 revision) Geneva: World Health Organisation, [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf]. Accessed18 January 2013, World Health Organisation.
30. National Department of Health Clinical guidelines for the management of HIV/AIDS in adults and adolescents 2010, Republic of South Africa: Department of Health, National Department of Health.
31. Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Barnighausen T. Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDS 2010, 25:163-170.
32. Boyer S, Clerc I, Bonono CR, Marcellin F, Bile PC, Ventelou B. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: Individual and healthcare supply-related factors. Soc Sci Med 2011, 72:1383-1392. 10.1016/j.socscimed.2011.02.030, 21470734.
33. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, Raffi F, Journot V, Moatti JP. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr 2001, 28:232-239.
34. Spire B, Carrieri P, Sopha P, Protopopescu C, Prak N, Quillet C, Ngeth C, Ferradini L, Delfraissy JF, Laureillard D. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Antivir Ther 2008, 13:697-703.
35. Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Le Coeur S, Diouf A, Fournier I, Schechter M, Chassany O. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV/AIDS. J Acquir Immune Defic Syndr 2012, 59:498-505. 10.1097/QAI.0b013e318245cafe, 22205438.
36. Duracinsky M, Lalanne C, Le Coeur S, Herrmann S, Berzins B, Armstrong AR, Lau JT, Fournier I, Chassany O. Psychometric validation of the PROQOL-HIV questionnaire, a new health-related quality of life instrument-specific to HIV disease. J Acquir Immune Defic Syndr 2012, 59:506-515. 10.1097/QAI.0b013e31824be3f2, 22293550.
37. Holzemer WL, Uys LR, Chirwa ML, Greeff M, Makoae LN, Kohi TW, Dlamini PS, Stewart AL, Mullan J, Phetlhu RD, Wantland D, Durrheim K. Validation of the HIV/AIDS Stigma Instrument - PLWA (HASI-P). AIDS Care 2007, 19:1002-1012. 10.1080/09540120701245999, 17851997.
38. Ukoumunne OC, Carlin JB, Gulliford MC. A simulation study of odds ratio estimation for binary outcomes from cluster randomized trials. Stat Med 2007, 26:3415-3428.
39. Mancl LA, DeRouen TA. A covariance estimator for GEE with improved small-sample properties. Biometrics 2001, 57:126-134. 10.1111/j.0006-341X.2001.00126.x, 11252587.
40. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. Aids 2009, 23(11):1397-1404. 10.1097/QAD.0b013e32832b7dca, 19381076.
41. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011, 8:CD009153.
42. World Health Organisation Guidance on Couples HIV Testing and Counselling including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples 2012, Geneva: World Health Organisation, Recommendations for a public health approach, In, World Health Organisation.
43. World Health Organisation Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013, Geneva: World Health Organisation, Recommendations for a public health approach, In, World Health Organisation.
44. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, Reid S, Mwango A, Mwinga A, Bulterys M, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009, 38(3):746-756. 10.1093/ije/dyp004, 2689395, 19223334.
45. Maqutu D, Zewotir T, North D, Naidoo K, Grobler A. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res 2010, 9(2):117-124. 10.2989/16085906.2010.517478, 3137932, 21779200.
46. Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009, 51(4):450-453. 10.1097/QAI.0b013e3181acb630, 19474757.
47. Barnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(52):21271-21276. 10.1073/pnas.1209017110, 3535659, 23223563.